Patient characteristics
| . | UMC/PMC (n = 276) . | MSK (n = 315) . |
|---|---|---|
| Median (range) age at transplantation, y | 7.06 (0.16-22.74) | 10.4 (0.1-35.6) |
| Sex, n | ||
| Male | 159 | 188 |
| Female | 117 | 127 |
| HCT source, n | ||
| BM (T-cell replete) | 100 | 61 |
| Unrelated cord blood | 172 | 40 |
| PBSCs | 4 | 6 |
| TCD PBSCs | 0 | 169 |
| TCD BM | 0 | 39 |
| Diagnosis, n | ||
| Malignancy | 139 | 220 |
| Metabolic inborn error | 51 | 1 |
| Hemoglobinopathy | 2 | 11 |
| Primary immune deficiency | 52 | 42 |
| BM failure | 29 | 40 |
| Autoimmune disease | 3 | 1 |
| aGVHD incidence by grade, n | ||
| 2 | 44 | 38 |
| 3 | 19 | 23 |
| 4 | 10 | 9 |
| Chronic (all) GvHD, n | 31 | 18 |
| Extensive | 7 | 11 |
| Conditioning regimen, n | ||
| TBI based | 26 | 112 |
| Chemotherapy based* | 250 | 203 |
| Serotherapy in conditioning, n (%) | 198 (72) | 227 (72) |
| Median (range) time to grade 2-4 aGVHD, d | 34 (6-205) | 55 (14-303) |
| Median (range) follow-up, d | 1293 (14-5017) | 750 (11-3780) |
| . | UMC/PMC (n = 276) . | MSK (n = 315) . |
|---|---|---|
| Median (range) age at transplantation, y | 7.06 (0.16-22.74) | 10.4 (0.1-35.6) |
| Sex, n | ||
| Male | 159 | 188 |
| Female | 117 | 127 |
| HCT source, n | ||
| BM (T-cell replete) | 100 | 61 |
| Unrelated cord blood | 172 | 40 |
| PBSCs | 4 | 6 |
| TCD PBSCs | 0 | 169 |
| TCD BM | 0 | 39 |
| Diagnosis, n | ||
| Malignancy | 139 | 220 |
| Metabolic inborn error | 51 | 1 |
| Hemoglobinopathy | 2 | 11 |
| Primary immune deficiency | 52 | 42 |
| BM failure | 29 | 40 |
| Autoimmune disease | 3 | 1 |
| aGVHD incidence by grade, n | ||
| 2 | 44 | 38 |
| 3 | 19 | 23 |
| 4 | 10 | 9 |
| Chronic (all) GvHD, n | 31 | 18 |
| Extensive | 7 | 11 |
| Conditioning regimen, n | ||
| TBI based | 26 | 112 |
| Chemotherapy based* | 250 | 203 |
| Serotherapy in conditioning, n (%) | 198 (72) | 227 (72) |
| Median (range) time to grade 2-4 aGVHD, d | 34 (6-205) | 55 (14-303) |
| Median (range) follow-up, d | 1293 (14-5017) | 750 (11-3780) |
BM, bone marrow; PBSC, peripheral blood stem cell.
Clofarabine, fludarabine, and busulfan.